The proteasome, a new target for cancer therapy

Related Experiment Video

Updated: Sep 21, 2026

Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors
08:08

Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors

Published on: February 27, 2015

S Gillessen1, M Groettup, T Cerny

  • 1Department of Oncology/Hematology, Kantonsspital St. Gallen, Switzerland. silke.gillessen@kssg.ch

Onkologie
|February 5, 2003
PubMed

Insights

The proteasome is a key cellular machine that degrades proteins. Proteasome inhibitors show promise as anticancer drugs by blocking cell proliferation and inducing apoptosis.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Background:

  • The proteasome is a crucial proteolytic system in eukaryotic cells.
  • It regulates key cellular processes like cell-cycle control, differentiation, and apoptosis.
  • Dysregulation of proteasome function is implicated in various diseases, including cancer.

Purpose of the Study:

  • To review the ubiquitin-proteasome pathway.
  • To outline recent advancements in proteasome inhibition for cancer therapy.

Main Methods:

  • This review synthesizes current research on the proteasome and its inhibitors.
  • It discusses the mechanism of action of proteasome inhibitors.
  • It examines their therapeutic potential in preclinical cancer models.

Main Results:

  • Proteasome inhibitors stabilize regulatory proteins, blocking cell proliferation.
  • These inhibitors induce apoptosis, a key mechanism in cancer cell death.
  • Proteasome inhibition can enhance sensitivity to conventional cancer treatments.

Conclusions:

  • Proteasome inhibition is a promising therapeutic strategy for cancer.
  • Further development of proteasome inhibitors holds significant clinical potential.
  • The ubiquitin-proteasome pathway remains an important target for drug discovery.

More Related Videos

Cell-Based Drug Screening for Inhibitors of Autophagy Related 4B Cysteine Peptidase09:51

Cell-Based Drug Screening for Inhibitors of Autophagy Related 4B Cysteine Peptidase

Published on: June 30, 2023

A Fluorescence-based Protocol for Preliminary Screening of Protein Synthesis Inhibitors from Natural Sources10:24

A Fluorescence-based Protocol for Preliminary Screening of Protein Synthesis Inhibitors from Natural Sources

Published on: January 27, 2026

Related Concept Videos

The Proteasome02:18

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Proteasome01:13

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
The Proteasome Structure01:17

The Proteasome Structure

The ubiquitin-proteasome pathway is a well-known mechanism utilized by eukaryotic cells to remove cytoplasmic proteins that are misfolded, damaged, or no longer needed. In this pathway, the protein that needs to be eliminated undergoes a process called ubiquitination, where a chain of ubiquitin molecules is attached to the 48th lysine residue of the target protein. This ubiquitin modification helps the proteasome distinguish between a target protein and a healthy protein.
The proteasome is an...